A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia
Public ClinicalTrials.gov record NCT01469039. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of ALKS 9072 in Subjects With Acute Exacerbation of Schizophrenia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study will determine the efficacy of ALKS 9072 (also known as aripiprazole lauroxil or ALKS 9070) for the treatment of schizophrenia in subjects experiencing an acute exacerbation.
Study identification
- NCT ID
- NCT01469039
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 623 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2011
- Primary completion
- Dec 31, 2013
- Completion
- Feb 28, 2014
- Last update posted
- Jan 29, 2019
2011 – 2014
United States locations
- U.S. sites
- 26
- U.S. states
- 12
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alkermes Investigational Site | Little Rock | Arkansas | 72201 | — |
| Alkermes Investigational Site | Little Rock | Arkansas | 72211 | — |
| Alkermes Investigational Site | Springdale | Arkansas | 72764 | — |
| Alkermes Investigational Site | Cerritos | California | 90703 | — |
| Alkermes Investigational Site | Garden Grove | California | 92845 | — |
| Alkermes Investigational Site | La Habra | California | 90631 | — |
| Alkermes Investigational Site | Oakland | California | 94612 | — |
| Alkermes Investigational Site | Oceanside | California | 92056 | — |
| Alkermes Investigational Site | Orange | California | 92868 | — |
| Alkermes Investigational Site | San Diego | California | 92123 | — |
| Alkermes Investigational Site | Washington D.C. | District of Columbia | 20016 | — |
| Alkermes Investigational Site | Fort Lauderdale | Florida | 33308 | — |
| Alkermes Investigational site | Leesburg | Florida | 34748 | — |
| Alkermes Investigational Site | Atlanta | Georgia | 30308 | — |
| Alkermes Investigational Site | Chicago | Illinois | 60640 | — |
| Alkermes Investigational Site | Hoffman Estates | Illinois | 60169 | — |
| Alkermes Investigational Site | Overland Park | Kansas | 66212 | — |
| Alkermes Investigational Site | Rockville | Maryland | 20850 | — |
| Alkermes Investigational Site | Creve Coeur | Missouri | 63141 | — |
| Alkermes Investigational Site | St Louis | Missouri | 63118 | — |
| Alkermes Investigational Site | Philadelphia | Pennsylvania | 19139 | — |
| Alkermes Investigational Site | Charleston | South Carolina | 29407 | — |
| Alkermes Investigational Site | Austin | Texas | 78731 | — |
| Alkermes Investigational Site | Austin | Texas | 78754 | — |
| Alkermes Investigational Site | Dallas | Texas | 75231 | — |
| Alkermes Investigational Site | Dallas | Texas | 75243 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 58 non-U.S. sites.
Recently updated Schizophrenia trials
Other public records listing Schizophrenia. Sorted by last update posted; newest first. Not a recommendation.
- NCT07615426: A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia Recruiting
- NCT07788755: NEURO-COGS: Neurometabolic Mechanisms of Cognitive Training in Schizophrenia Not yet recruiting
- NCT07783373: Long-Term Real-World Safety of Cobenfy in Adults With Schizophrenia Active, not recruiting
- NCT07772349: Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 3) Not yet recruiting
- NCT07680114: Overnight Thalamic TES-TI to Modulate Sleep Spindles in Individuals With Schizophrenia Spectrum Disorders and Matched Healthy Controls Recruiting
- NCT07734493: A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01469039, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 29, 2019 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01469039 live on ClinicalTrials.gov.